Poniard Pharmaceuticals, Inc.
PARD
$0.0001
$0.000.00%
OTC PK
| 09/30/2011 | 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.84M | 16.04M | 16.53M | 18.43M | 18.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.72M | 16.52M | 18.66M | 25.12M | 32.58M |
| Operating Income | -13.72M | -16.52M | -18.66M | -25.12M | -32.58M |
| Income Before Tax | -16.04M | -18.72M | -21.41M | -30.05M | -38.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.04 | -18.72 | -21.41 | -30.05 | -38.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.04M | -18.72M | -21.41M | -30.05M | -38.05M |
| EBIT | -13.72M | -16.52M | -18.66M | -25.12M | -32.58M |
| EBITDA | -12.44M | -15.23M | -17.36M | -23.80M | -31.25M |
| EPS Basic | -11.92 | -14.76 | -17.69 | -26.79 | -36.89 |
| Normalized Basic EPS | -6.49 | -8.51 | -10.33 | -14.76 | -20.63 |
| EPS Diluted | -11.92 | -14.76 | -17.74 | -26.90 | -37.00 |
| Normalized Diluted EPS | -6.49 | -8.51 | -10.33 | -14.76 | -20.63 |
| Average Basic Shares Outstanding | 5.55M | 5.26M | 4.96M | 4.68M | 4.40M |
| Average Diluted Shares Outstanding | 5.55M | 5.26M | 4.96M | 4.68M | 4.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.20% | -1.03% | -0.90% | -0.64% | -0.91% |